Sikarin PCL is a Thailand-based company operating in the healthcare sector. It operates private hospitals located in eastern Bangkok, Samutprakarn Province and Hat Yai District, Songkhla Province namely Sikarin Hospital, Sikarin Samut Prakan Hospital, and Sikarin Hat Yai Hospital. Its services include general surgery services, obstetrics, aesthetic center, dental center, orthopedic center, checkup center, emergency and trauma center, and children center, among others.
1994
3.0K+
LTM Revenue n/a
LTM EBITDA n/a
$421M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sikarin has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Sikarin achieved revenue of $178M and an EBITDA of $42.0M.
Sikarin expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Sikarin valuation multiples based on analyst estimatesFY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $171M | $178M | XXX | XXX | XXX |
Gross Profit | $59.8M | $58.8M | XXX | XXX | XXX |
Gross Margin | 35% | 33% | XXX | XXX | XXX |
EBITDA | $48.8M | $42.0M | XXX | XXX | XXX |
EBITDA Margin | 29% | 24% | XXX | XXX | XXX |
Net Profit | $29.7M | $26.2M | XXX | XXX | XXX |
Net Margin | 17% | 15% | XXX | XXX | XXX |
Net Debt | n/a | $1.1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Sikarin's stock price is THB 7 (or $0).
Sikarin has current market cap of THB 14.7B (or $432M), and EV of THB 14.3B (or $421M).
See Sikarin trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$421M | $432M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Sikarin has market cap of $432M and EV of $421M.
Sikarin's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Sikarin's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Sikarin and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $421M | XXX | XXX | XXX |
EV/Revenue | 2.4x | XXX | XXX | XXX |
EV/EBITDA | 10.0x | XXX | XXX | XXX |
P/E | 22.2x | XXX | XXX | XXX |
P/E/Growth | n/a | XXX | XXX | XXX |
EV/FCF | 15.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSikarin's NTM/LTM revenue growth is n/a
Sikarin's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $9K for the same period.
Over next 12 months, Sikarin's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Sikarin's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Sikarin and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | 4% | XXX | XXX | XXX | XXX |
EBITDA Margin | 24% | XXX | XXX | XXX | XXX |
EBITDA Growth | -14% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
Opex per Employee | $9K | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | 15% | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
Opex to Revenue | 15% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Burjeel Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
PureHealth | XXX | XXX | XXX | XXX | XXX | XXX |
Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
Ramsay Health | XXX | XXX | XXX | XXX | XXX | XXX |
Compass Pathways | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sikarin acquired XXX companies to date.
Last acquisition by Sikarin was XXXXXXXX, XXXXX XXXXX XXXXXX . Sikarin acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was Sikarin founded? | Sikarin was founded in 1994. |
Where is Sikarin headquartered? | Sikarin is headquartered in Thailand. |
How many employees does Sikarin have? | As of today, Sikarin has 3.0K+ employees. |
Is Sikarin publicy listed? | Yes, Sikarin is a public company listed on BKK. |
What is the stock symbol of Sikarin? | Sikarin trades under SKR ticker. |
When did Sikarin go public? | Sikarin went public in 1988. |
Who are competitors of Sikarin? | Similar companies to Sikarin include e.g. Burjeel Holdings, PureHealth, Integral Diagnostics, Ramsay Health. |
What is the current market cap of Sikarin? | Sikarin's current market cap is $432M |
What is the current revenue growth of Sikarin? | Sikarin revenue growth between 2023 and 2024 was 4%. |
Is Sikarin profitable? | Yes, Sikarin is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.